Libre 2 Android App Cleared in US; CytoDyn Reports Positive Leronlimab NASH Data; Kadimastem Raises $3.2 to Support T1DM Cell Therapy Development; Integrity Applications Changes Name to GlucoTrack, Inc.
A series of cardiometabolic-related news items have been observed: It has been observed that the Libre 2 Android app recently received FDA clearance (view FDA 510(k) database); CytoDyn announced positive data from the leronlimab open-label NASH trial; Kadimastem announced it has raised $3.2M from ILEX Medical in a private financing round to support Kadimastem’s T1DM and ALS cell therapy development programs; and Integrity Applications announced it has changed its name to GlucoTrack, Inc. Below, FENIX provides highlights and insights for the respective new items.
This content is for Read Less members only.
Register
Register
Already a member? Log in here